Retatrutide
Retatrutide is an investigational triple agonist targeting GIP, GLP-1, and glucagon receptors. Phase 2 trials showed unprecedented weight loss of up to 24% at 48 weeks, making it potentially the most effective obesity treatment studied.
Mechanism of Action
Triple receptor activation provides complementary metabolic effects: GLP-1 and GIP reduce appetite and improve insulin sensitivity, while glucagon receptor activation increases energy expenditure and promotes hepatic fat oxidation.
Typical Dosage (Research)
Clinical trials used doses from 1mg to 12mg weekly. Optimal dosing still being determined in ongoing Phase 3 trials.
Subcutaneous injection once weekly. Currently only available through clinical trials - not yet FDA approved.
Side Effects & Risks
Similar GI effects to other incretin-based therapies: nausea, diarrhea, vomiting, constipation. Dose-dependent severity.
Still investigational - full safety profile being established. Expected similar warnings to GLP-1 class regarding thyroid, pancreatitis, and gallbladder.
Who Uses Retatrutide
Currently only available to clinical trial participants. Expected approval would target severe obesity and metabolic syndrome.